HTG Molecular Diagnostics Raises $16.2M
HTG Molecular Diagnostics, a Tuscon-based provider of molecular technology, has raised $16.2 million in Series D financing. Investors include SR One, the corporate venture capital arm of GlaxoSmithKline, as well as Novo A/S, Fletcher Spaght Ventures, Merck Capital Ventures, Solstice Capital and Valley Ventures. Novo A/S led the round. Simeon George, partner at SR One will now join the company’s board.
13 June 2011•2 mins read
